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Sunday, February 8, 2015 19asignificant effect of the toxin is found, possibly related to decreased lipid
mobility [4].
Here we will provide an overview of membrane texture in a range of systems
and describe our efforts to understand and systematize the observations.
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Giant plasma membrane vesicles (GPMVs) isolated from mammalian cell
lines contain coexisting liquid phases at low temperature, a single liquid
phase at elevated temperatures, and undergo robust micron-sized critical fluc-
tuations near the miscibility transition which is typically close to room tem-
perature. In past work, we have measured the temperature dependence of
critical composition fluctuations and speculated that mammalian cells tune
their membrane composition to maintain a room temperature critical point
in order to experience <100nm super-critical composition fluctuations under
growth conditions of 37C [1]. Here, we present evidence that cells actively
tune membrane critical temperatures (Tc) to a specific temperature difference
below growth temperatures by preparing GPMVs from ZF4 cells, a zebrafish
cell line that is capable of growing at temperatures ranging between 20 and
32C. As was the case in mammalian cell lines, ZF4 cells produce GPMVs
with coexisting liquid phases at low temperature and micron-sized critical
fluctuations near the miscibility transition. ZF4 derived GPMVs transition
temperatures shift to lower values when cells are grown at lower temperature,
such that Tc was 16.851.2C below growth temperatures for ZF4 cells
grown between 20 and 32C. We also examined the time-course of Tc adjust-
ment by preparing GPMVs from cells adapted for growth at 28C then sub-
sequently grown at 20C. Transition temperatures adjust with a time-constant
of 1.5 days, in good correspondence with the doubling time under these
growth conditions.
1.S.L. Veatch, P. Cicuta, P. Sengupta, A. Honerkamp-Smith, D. Holowka, B.
A. Baird. ACS Chem Biol. 2008 3(5):287-93. (2008)Platform: Ion Channels, Pharmacology, and
Disease
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The ability of amantadine to block wild-type influenza A M2 is profoundly
influenced by its position and orientation in the channel, which in turn affect
the drug’s hydration state, according to molecular dynamics simulations. Um-
brella sampling results reveal that amantadine has strong binding free energy in
wild-typeM2, accompanied by low lateral water density, when it is initially ori-
ented with its amine toward the C-terminus of the protein and its adamantane
cage is positioned between Ser31 alpha carbons and in contact with the Val27
side chains. In critical regions of the reaction coordinate, simulations show that
the drug frequently rotates to this orientation even when started in the opposite
orientation. In contrast, the prevailing influenza A M2 mutant (S31N) shows no
significant difference in the likelihood of amantadine orientation-reversal be-
tween simulations of opposite initial orientation. Furthermore, in free simula-
tions of the S31N, the drug shows a high propensity to drop deeper into the
channel, where lateral water density becomes high. High lateral water density
should facilitate proton transport past the drug: the drug binds but does not
block. The differences in amantadine behavior between the Ser31 and Asn31
variants suggest that residue 31 plays a key role in orientation- and position-
specific block of M2 by amantadine and that an Asn31 mutation increases
mobility and rotational freedom of amantadine in the mutant M2 (S31N).
Consequently, the success of future anti-influenza drugs may depend on their
ability to adopt specific orientations as they plug the Val27-lined opening of
the channel.93-Plat
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CFTR is the only member of the ATP-binding cassette (ABC) protein super-
family that functions as an ion channel. Once its regulatory (R) domain is phos-
phorylated, CFTR will harness the free energy from ATP binding/hydrolysis in
the nucleotide-binding domains (NBDs) to power the conformational changes
of the gate located in the transmembrane domains (TMDs). We inadvertently
found that some permeant anions such as nitrate or bromide, when applied to
the cytoplasmic side of the channel, can increase the Po of CFTR by raising
slightly the opening rate but decreasing considerably the closing rate. Since ni-
trate also decelerates non-hydrolytic closing, we conclude that the effect of ni-
trate is independent of ATP hydrolysis. Surprisingly, despite their markedly
different physical properties, the gating effects of nitrate are remarkably similar
to those of VX-770, a well-characterized CFTR potentiator now used in clinics.
Nonetheless, while VX-770 is equally effective when applied from either side
of the membrane, nitrate potentiates gating mainly from the cytoplasmic side,
implicating a common mechanism for gating modulation but via two distinct
sites of action. Since nitrate increases the Po of DR- as well as DNBD2-
CFTR, we exclude the R domain and NBD dimer as potential targets for nitrate.
Furthermore, for both G551D- andDNBD2-CFTR, two mutants with extremely
low Po, we show that the fold-increase of the Po by nitrate plus VX-770 is virtu-
ally the same as the product of fold increases by individual reagents. Collec-
tively, our data suggest that nitrate and VX-770 independently affect CFTR
gating by shifting the equilibrium of gating conformational changes of the
TMDs towards the open channel configuration. These results may not only
shed light on the future development of novel therapeutical reagents, but also
provide insights into the coupling mechanism of gate opening/closing and
NBD dimerization/dissociation.
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The g-amino butyric acid type A (GABA(A)) receptor is an ionotropic receptor
critical for inhibitory signaling in the central nervous system. GABA(A) recep-
tors are positively modulated by numerous general anesthetics and likely
contribute to the effects of general anesthesia. Several site-directed mutagen-
esis and photoaffinity labeling experiments have suggested numerous potential
binding sites for general anesthetics, as well as other modulators of GABA(A)
receptors including neurosteroids and thyroid hormone. The absolute affinities
of the modulator for each site are unknown, however, making it challenging to
determine which of the many sites is occupied at clinical concentrations. Mea-
surement of modulator affinity for individual sites is challenging experimen-
tally, while isolation of individual sites in computational methods is
relatively straightforward. Here we use the Alchemical Free Energy Perturba-
tion (AFEP) method combined with molecular dynamics simulations to calcu-
late absolute binding affinities of propofol and sevoflurane for pore and
intersubunit sites on a homology model of an a1b3g2 GABA(A) receptor, after
initial coordinates were determined with automated docking. We calculate sig-
nificant differences in general anesthetic affinity for pore and intersubunit sites
at various interfaces, consistent with a complex dose-response curve in which
low affinity sites are associated with inhibition and high affinity sites are asso-
ciated with potentiation.
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Cystic fibrosis (CF) is usually caused by F508del mutation in the CFTR gene.
Normally, CFTR protein aids in salt transport across the apical surface of
epithelia, keeping their surface hydrated. F508del results in decreased surface
expression of CFTR, leading to dehydration of the surface. This makes the lung
20a Sunday, February 8, 2015epithelium prone to infection and in intestine leads to obstruction. Patients ho-
mozygous for F508del, have a tremendous variation in the severity of disease.
Recent Genome-wide association studies indicate that this variation is due to
presence of modifier genes, with SLC6A14 as the top modifier (Sun
et.al.,2012). SLC6A14 is a Naþ/Cl- dependent cationic/neutral amino-acid
transporter on the surface of lung and colonic epithelium. As both transporters
are expressed apically, we hypothesized that SLC6A14 would modify the fluid
secretory capacity of the epithelium. So in collaboration with TCP, we gener-
ated a SLC6A14 knock-out mouse. We can measure in-vivo fluid secretion in
mice, using an intestinal closed-loop assay. SLC6A14 knock-out mice ex-
hibited a decrease in cAMP stimulated fluid secretion mediated via CFTR rela-
tive to Wt control. To explore the mechanism by which this modification
occurs, we utilized a BHK heterologous expression system, overexpressing
CFTR and SLC6A14. Interestingly, the functional interaction can be recapitu-
lated in this system, suggesting that it not tissue-type dependent. Preliminary
biochemical and anion-flux studies support the hypothesis that SLC6A14
does not affect the processing or stability of Wt or F508del-CFTR proteins
rather it augments the activity of these channel proteins once localized to the
cell surface. Future studies will focus on understanding if this augmentation
is related to modification of CFTR’s phosphorylation dependent gating. These
results show a positive impact of SLC6A14 on CFTR channel function and
fluid secretion, providing an alternative drug target for CF patients.
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HVCN1 is the only mammalian voltage-gated proton channel. In human B lym-
phocytes, HVCN1 associates with the B Cell Receptor (BCR) and is required
for optimal BCR signaling and redox control. HVCN1 is expressed in malig-
nant B cells that rely on BCR signaling, such as Chronic Lymphocytic Leuke-
mia (CLL) cells. Compared with normal B lymphocytes, HVCN1S expression
is higher in B-cell lines and in B cells from patients with Chronic Lymphocytic
Leukemia. We found that HVCN1 was expressed in B cells as two protein iso-
forms. The shorter isoform (HVCN1S) was enriched in B cells from a cohort of
76 CLL patients. When overexpressed in a B-cell lymphoma line, HVCN1S re-
sponded more profoundly to PKC-dependent phosphorylation. This more
potent enhanced gating response was mediated by increased phosphorylation
of the same residue responsible for enhanced gating in HVCN1L, Thr
29.
Although B cells from CLL patients expressed both isoforms, their PMA
response was comparable with that of cells heterologously expressing HVCN1S
alone, indicating that this isoform dominates. Furthermore, the association of
HVCN1S with the BCR was weaker, which resulted in its diminished internal-
ization upon BCR stimulation. Finally, HVCN1S conferred a proliferative and
migratory advantage, as well as enhanced BCR-dependent signaling. Overall,
our data show for the first time the existence of a shorter isoform of HVCN1
with enhanced gating that is specifically enriched in malignant B cells.
HVCN1S properties suggest it may contribute to the pathogenesis of BCR
dependent B-cell malignancies.
Support: Bennett Fellowship from Leukaemia and Lymphoma Research (MC);
GSK Oncology - BBSRC CASE PhD studentship (MB); NIH grant
R01GM102336 (TD).
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Small-conductance (KCa2) and intermediate-conductance (KCa3.1) calcium-
activated Kþ channels are voltage-independent and share a common calcium/
calmodulin mediated gating mechanism. Existing positive gating modulators
like EBIO, NS309 or SKA-31 activate both KCa2 and KCa3.1 channels with
similar potency or, as in the case of CyPPA and NS13001, selectively activate
KCa2.2 and KCa2.3 channels. We recently performed a structure activity rela-tionship (SAR) study with the aim of optimizing the benzothiazole pharmaco-
phore of SKA-31 towards KCa3.1 selectivity and have identified SKA-121
(5-methylnaphtho[2,1-d]oxazol-2-amine), which displays 41-fold selectivity
for KCa3.1 (EC50 109 nM 5 14 nM) over KCa2.3 (EC50 4.4 5 1.6 mM).
SKA-121 is 200-400 fold selective over representative KV (KV1.3, KV2.1,
KV3.1 and KV11.1), NaV (NaV1.2, NaV1.4, NaV1.5 and NaV1.7) as well
as CaV1.2 channels. SKA-121 is a typical positive-gating modulator, which
shifts the calcium-concentration response curve of KCa3.1 to the left but
also increases open probability at saturating Ca2þ concentrations. In order to
understand why introduction of a ‘‘simple’’ CH3 group in 5-position of the ben-
zothiazole/oxazol system could achieve such a significant gain in selectivity for
KCa3.1 over KCa2.3 we are currently performing site-directed mutagenesis of
the calmodulin binding domain (CaMBD) guided by structural modeling. We
used the RosettaLigand method to generate preliminary models of SKA-121
binding to our model of the KCa3.1 C-terminal CaMBD in complex with
calmodulin. Our most energetically favorable model suggests that SKA-121
is positioned in close proximity to F301, R362, V365, M368, V369, and
S372 in KCa3.1.
Supported by U54NS079202, T32-GM008799 and T32 HL 086350 from NIH.
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Microglia rapidly respond to CNS injury and disease and can assume a spec-
trum of activation states that are reflected by changes in gene expression. Clas-
sical activation (often induced by lipopolysaccharide) and alternative activation
(IL4-induced) are now well studied but less is known about acquired de-
activation in response to IL10. Here, we are addressing how microglial
activation states affect their migration and invasion; crucial functions in the
developing CNS and after injury in adults.
We found that LPS-treated rat microglia migrate very poorly; whereas, IL4- or
IL10-treated cells migrated and invaded much better than resting cells. Never-
theless, there were similarities and differences in gene induction by IL4 and
IL10. The lamellum of migrating microglia contains a large ring of podoso-
mes_microscopic structures that are thought to mediate adhesion, migration
and invasion. IL10 (not IL4) increased podosome expression.
Then, based on the observed enrichment of SK3 Ca2þ-activated potassium
channels in podosomes, we predicted that it regulates migration and invasion.
KCNN3 (SK3) expression was similar under all three activation conditions and
KCa2.3 currents were observed. A surprising finding was that, of the three SK3
inhibitors tested (apamin, tamapin, NS8593); only NS8593 reduced the migra-
tion and invasion of IL4- or IL10-activated microglia. Surprisingly, in addition
to blocking SK3, we found that NS8593 blocked TRPM7 channels in micro-
glia. We confirmed that TRPM7 (not SK3) regulates migration and invasion
by using a TRPM7 inhibitor (AA-861) that does not block SK3 channels.
We conclude that TRPM7 (not SK3) contributes to the enhanced ability of mi-
croglia to migrate and invade when in anti-inflammatory states. This will be an
important consideration in the current efforts to develop TRPM7 inhibitors for
treating CNS injury.
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Retigabine is the prototypical member of a recently discovered class of anti-
epileptic drugs that act by potentiating the neuronal M-current formed by
KCNQ2-5 potassium channel subunits. Retigabine interacts with the pore of
KCNQ2-5 channels, requiring a Trp residue present in KCNQ2-5 to exert its
effects, suggesting the notion of a hydrophobic binding pocket. We have
used nonsense suppression to subtly alter the properties of this Trp residue
(265) in homomeric KCNQ3 channels and identify the specific chemical inter-
actions required for retigabine effects. Remarkably, simply changing the posi-
tion of the indole nitrogen atom from Trp265 (removing its hydrogen bonding
